Patents Assigned to NEXTCURE, INC.
  • COMPOSITIONS AND METHODS FOR MODULATING FLRT3 MEDIATED SIGNAL TRANSDUCTION
    Publication number: 20230357384
    Abstract: Compositions and methods of use thereof for modulating FLRT3 mediated signaling are provided. For example, immunomodulatory agents are provided that reduce FLRT3 expression, ligand binding, crosslinking, FLRT3 mediated signaling, or a combination thereof. In another embodiment, immunomodulatory agents are provided that enhance or promote FLRT3 expression, ligand binding, crosslinking, FLRT3 mediated signaling, or a combination thereof. Such agents can be used to modulate an immune response in a subject in need thereof.
    Type: Application
    Filed: June 21, 2021
    Publication date: November 9, 2023
    Applicant: NEXTCURE, INC.
    Inventors: Dallas Benjamin FLIES, Kushal PRAJAPATI, Adem Can KOKSAL, Linda LIU, Solomon LANGERMANN
  • Antibodies for Siglec-15 and methods of use thereof
    Patent number: 11390675
    Abstract: Siglec-15 binding molecules are provides. The molecules are typically an antibody or antigen binding fragment thereof that immunospecifically binds to Siglec-15. Siglec-15 ligand-binding molecules are also provided. The molecules are typically Siglec-15 polypeptide or fusion protein. Methods of using the molecules to reduce Siglec-15 mediated immunosuppression in a subject in need thereof are also provided.
    Type: Grant
    Filed: September 21, 2017
    Date of Patent: July 19, 2022
    Assignee: NEXTCURE, INC.
    Inventors: Linda Liu, Benjamin Dallas Flies, Solomon Langermann